Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Sponsor: European Network of Gynaecological Oncological Trial Groups (ENGOT)
Terminated
Study Terminated by Sponsor
This PHASE3 trial investigates Fallopian Tube Cancer and High Grade Serous Ovarian Cancer and is currently terminated or withdrawn. European Network of Gynaecological Oncological Trial Groups (ENGOT) leads this study, which shows 14 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jul 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- GOG Foundation
- Mersana Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .